DiscoverOncology On The GoS2 Ep14: Treatment Options for Relapsed/Refractory Small Cell Lung Cancer
S2 Ep14: Treatment Options for Relapsed/Refractory Small Cell Lung Cancer

S2 Ep14: Treatment Options for Relapsed/Refractory Small Cell Lung Cancer

Update: 2021-12-02
Share

Description

In the second part of a 4-part series on small cell lung cancer, CancerNetwork continued its conversation with Wade Iams, MD, a thoracic medical oncologist at the Vanderbilt University Medical Center. Iams turned the attention to different treatment options for patients with relapsed/refractory small cell lung cancer. Among others, Iams touched on lurbinectedin, topotecan, and some of the crucial clinical trials associated with treatment options for small cell lung cancer, including a phase 2 basket trial and phase 3 ATLANTIS trial examining lurbinectedin.



Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.



Check out the first episode of this series on first-line therapeutic options in small cell lung cancer.
Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

S2 Ep14: Treatment Options for Relapsed/Refractory Small Cell Lung Cancer

S2 Ep14: Treatment Options for Relapsed/Refractory Small Cell Lung Cancer

CancerNetwork